WalkMe First Quarter 2024 Earnings: EPS Beats Expectations

Advertisement

WalkMe (NASDAQ:WKME) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$68.6m (up 4.1% from 1Q 2023).
  • Net loss: US$6.15m (loss narrowed by 77% from 1Q 2023).
  • US$0.067 loss per share (improved from US$0.30 loss in 1Q 2023).
earnings-and-revenue-growth
NasdaqGS:WKME Earnings and Revenue Growth May 24th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

WalkMe EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 44%.

Looking ahead, revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Software industry in the US.

Performance of the American Software industry.

The company's shares are up 3.9% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for WalkMe that you need to be mindful of.

Valuation is complex, but we're here to simplify it.

Discover if WalkMe might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:WKME

WalkMe

Provides cloud-based digital adaption platform and associated professional services in the United States and internationally.

Flawless balance sheet and fair value.

Advertisement

Weekly Picks

DA
davidlsander
NAUF.F logo
davidlsander on Nevgold ·

The U.S. Government Is Desperate for This Metal. This Tiny Miner Has It -- Its Closest Peer Is Already Worth Double.

Fair Value:US$2.1946.6% undervalued
39 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.0% undervalued
62 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
JD
CELH logo
JD009 on Celsius Holdings ·

From $5M to $2B: Why the 2024 Crash Was the Best Buying Opportunity in Consumer Stocks

Fair Value:US$55.4347.7% undervalued
22 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative
WA
ACN logo
Wavefarer on Accenture ·

High-quality global services company facing an AI-driven valuation reset.

Fair Value:US$30152.3% undervalued
17 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

RO
RockeTeller
SVRS logo
RockeTeller on Silver Storm Mining ·

Silver Storm Mining, 34 Million Oz Produced, Now Targeting Q2 2026 Restart

Fair Value:CA$8.8495.5% undervalued
13 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative
RO
Robbo
MSFT logo
Robbo on Microsoft ·

Is Microsoft on sale? and Its Case in the AI Race

Fair Value:US$4042.5% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
RARE logo
AnimalDoctorKwon on Ultragenyx Pharmaceutical ·

burns cash despite four approved drugs, trapped by structural inefficiencies and gene-therapy scaling hurdles that thin safety margins.

Fair Value:US$2612.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75027.5% undervalued
96 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
BL
BlackGoat
CBRS logo
BlackGoat on Cerebras Systems ·

The Wafer Giant Threatening NVIDIA's GPU Hegemony

Fair Value:US$415.5458.4% undervalued
64 users have followed this narrative
3 users have commented on this narrative
11 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.0% undervalued
62 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative